This study investigated the safety, clinical activity and patient-reported outcomes of patients with diffuse-type tenosynovial giant-cell tumour (dTGCT) of the soft tissue who were treated with emactuzumab, a humanised anti-colony stimulating factor 1 receptor (CSF-1R) monoclonal antibody and were followed up for up to 2 years after the start of treatment.
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
© SynOx Therapeutics. Last Revised: July 2022.
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
© SynOx Therapeutics. Last Revised: July 2022.